Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal sufentanil/ketamine (CT001) in pediatric acute pain
NCT06364072Phase 3Completed
- Sponsor
- Cessatech
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Small Molecules, Blood Coagulation Factors
- Countries
- 2
01
Overview
A Phase 3 trial of CT001 in acute pain, sponsored by Cessatech. Started May 2024; status: completed.
02
Drugs
CT001
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT06364072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364072.